KR100511544B1 - Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제 - Google Patents

Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제

Info

Publication number
KR100511544B1
KR100511544B1 KR10-2004-7015736A KR20047015736A KR100511544B1 KR 100511544 B1 KR100511544 B1 KR 100511544B1 KR 20047015736 A KR20047015736 A KR 20047015736A KR 100511544 B1 KR100511544 B1 KR 100511544B1
Authority
KR
South Korea
Prior art keywords
seq
human
antibodies
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2004-7015736A
Other languages
English (en)
Korean (ko)
Other versions
KR20040101388A (ko
Inventor
로버트 에스. 아메스
에드워드 로버트 아펠바움
어윈 엠. 차이켄
리차드 엠. 쿡
미첼 스튜어트 그로스
스티븐 더들리 호움즈
리네트 제인 맥밀란
티모시 웨인 씨쎈
Original Assignee
스미스클라인 비참 코포레이션
스미스클라인비이참피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스클라인 비참 코포레이션, 스미스클라인비이참피이엘시이 filed Critical 스미스클라인 비참 코포레이션
Priority claimed from PCT/US1995/017082 external-priority patent/WO1996021000A2/en
Publication of KR20040101388A publication Critical patent/KR20040101388A/ko
Application granted granted Critical
Publication of KR100511544B1 publication Critical patent/KR100511544B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2004-7015736A 1994-12-23 1995-12-22 Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제 Expired - Lifetime KR100511544B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/363,131 1994-12-23
US08/467,420 1995-06-06
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 1995-06-06
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1019970704320A Division KR100509993B1 (ko) 1994-12-23 1995-12-22 Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제

Publications (2)

Publication Number Publication Date
KR20040101388A KR20040101388A (ko) 2004-12-02
KR100511544B1 true KR100511544B1 (ko) 2005-08-31

Family

ID=23428947

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7015736A Expired - Lifetime KR100511544B1 (ko) 1994-12-23 1995-12-22 Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제

Country Status (11)

Country Link
US (5) US5683892A (enExample)
EP (1) EP1749840A3 (enExample)
JP (2) JP5177444B2 (enExample)
KR (1) KR100511544B1 (enExample)
CN (1) CN101353381A (enExample)
CY (2) CY2592B2 (enExample)
FR (1) FR15C0089I2 (enExample)
HU (1) HUS1500070I1 (enExample)
NO (1) NO2018035I1 (enExample)
PT (1) PT800536E (enExample)
ZA (1) ZA9510965B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190126769A (ko) * 2016-12-23 2019-11-12 세파론, 인코포레이티드 항-il-5 항체

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
FR2783326B1 (fr) * 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7718076B1 (en) 2006-02-14 2010-05-18 Charles Lonnie Meurer Methods of and common gantry drive for single-pass cleaning of multiple stages of a material separation and removal system
US7314572B1 (en) 2006-02-14 2008-01-01 Meurer Research, Inc. Methods of and apparatus for low-angle-tray settling with multi-zone configuration
US7780015B1 (en) 2006-08-24 2010-08-24 Meurer Research, Inc. Methods of and sludge collector with adjacent opposed oppositely-moving blades for moving sludge in a basin
WO2008134724A2 (en) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
US7560035B1 (en) 2007-06-22 2009-07-14 Charles Lonnie Meurer Overhead trough with constant trough flow velocity configuration and methods of regulating trough flow velocity
KR20100134702A (ko) 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CA3052070A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
IL268568B2 (en) 2017-02-10 2024-03-01 Mayo Found Medical Education & Res TRAILshort ANTIBODY AND METHODS OF USE
SMT202600240T1 (it) * 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
CN110913887A (zh) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
WO2019062831A1 (zh) 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2026064362A1 (en) * 2024-09-18 2026-03-26 The Children's Hospital Of Philadelphia Antibodies and chimeric antigen receptors binding to p2rx5 and methods of use for treating cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
WO1990004979A2 (en) * 1988-11-03 1990-05-17 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2128511C (en) * 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190126769A (ko) * 2016-12-23 2019-11-12 세파론, 인코포레이티드 항-il-5 항체
KR102651290B1 (ko) * 2016-12-23 2024-03-25 세파론 엘엘씨 항-il-5 항체
US12577298B2 (en) 2016-12-23 2026-03-17 Cephalon Llc Anti-IL-5 antibodies

Also Published As

Publication number Publication date
US6946130B2 (en) 2005-09-20
US5851525A (en) 1998-12-22
EP1749840A2 (en) 2007-02-07
HUS1500070I1 (hu) 2017-07-28
US20040156850A1 (en) 2004-08-12
CY2015056I1 (el) 2016-08-31
CN101353381A (zh) 2009-01-28
US5693323A (en) 1997-12-02
US20030059429A1 (en) 2003-03-27
FR15C0089I2 (fr) 2016-07-01
JP2010077133A (ja) 2010-04-08
JP2013091636A (ja) 2013-05-16
EP1749840A3 (en) 2008-10-15
CY2015056I2 (el) 2016-06-22
NO2018035I1 (no) 2018-10-04
JP5177444B2 (ja) 2013-04-03
PT800536E (pt) 2007-02-28
US5683892A (en) 1997-11-04
ZA9510965B (en) 1996-09-16
CY2592B2 (en) 2009-11-04
FR15C0089I1 (enExample) 2016-12-02
KR20040101388A (ko) 2004-12-02

Similar Documents

Publication Publication Date Title
US20040156850A1 (en) Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
CN100391977C (zh) 用于治疗il-5介导的疾病的重组il-5拮抗剂
WO1996021000A9 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
WO1997048418A1 (en) Improved method for treatment and diagnosis of il-5 mediated disorders
EP2426143B1 (en) Method of providing disease-specific binding molecules and targets
AU2016363696B2 (en) Single variable domain T-cell receptors
WO1998005787A1 (en) A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998005787A9 (en) A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
ES2990881T3 (es) Composición de inhibidor de IL-1BETA y uso de la misma
AU2021202315A1 (en) Hybrid immunoglobulin containing non-peptidyl linkage
AU734997B2 (en) Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US11155600B2 (en) Human IL1-R1 derived inhibitor of IL-1β
US12180264B2 (en) IL1-R1 derived inhibitor of IL-1β and use thereof
WO2016034891A1 (en) Anti-hepatitis c antibodies and antigen binding fragments thereof
US20040077573A1 (en) Method for regulating the activity of an expression product of a gene transferred into living body
CN115768787A (zh) IL1-R1衍生的IL-1β抑制剂及其用途
AU775429B2 (en) A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
HK40081430A (en) IL1-R1 DERIVED INHIBITOR OF IL-1β AND USE THEREOF
TW202227635A (zh) 載體化抗體及其用途
EA051567B1 (ru) Гуманизированные антитела против irhom2

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20041004

Application number text: 1019970704320

Filing date: 19970623

PA0201 Request for examination
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041129

Patent event code: PE09021S01D

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050630

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050824

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050825

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080704

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090709

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100729

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110728

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130729

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130729

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20140730

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140730

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 11

End annual number: 11

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20160622

Termination category: Expiration of duration